Clintrak Pharmaceutical Services, LLC (CPS) Signs Lease for its Freiburg, Germany Facility and Establishes Clintrak Pharmaceutical Services GmbH as its European Base of Operation
CPS is pleased to announce that it has agreed to terms and signed the lease for its new facility in Freiburg, Germany.
23 May 2005 -- Freiburg, Germany: CPS is pleased to announce that it has agreed to terms and signed the lease for its new facility in Freiburg, Germany. The state-of-the-art facility is approximately 3,500 m2 (35,000 ft. 2) and will require minor modifications to become fully operational as the company's Clinical Trial Material (CTM) Packaging and Logistics center in Europe. The company will also be housing its European label reprinting capability from this site which will allow it to provide reprints of all labels including its flagship GlobalPly Booklet Labels. CPS anticipates that the facility will be available for audits by 1 August 2005. The new facility will be known as CPS GmbH.
In addition to the facility, the third version of the company's proprietary Clinical Trial Material Software (CTMS) will be completed and validated. CTMS 3.0 will encompass all requirements for the German facility as well as additional functionality for on-going operations. The software, which is compliant with 21 CFR Part 11, will manage all areas of the company's operation and provides seamless data for the company's clients. Brian Jusas, CEO, stated "the ability to utilize CTMS for all activities within our CTM operations, at both sites, is critical in providing clean, real-time data that has not been transferred or manipulated prior to provision to our clients."
Philippe Muller, who has joined the organization as Director, Qualified Person is very excited with the new facility stating "the acquisition of this facility will allow CPS to move rapidly to service the needs of the CTM industry throughout Europe".
CPS is a privately held company which provides CTM Label and Logistics solutions to Pharmaceutical and Biotechnology industry.
For more information, please contact Charles J. Gettis, Vice President, Corporate Development at cgettis@acculogix-usa.com or +215.826.8002 or Philippe Muller, Director, Qualified Person at +49 76150380.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
